Novo Nordisk (NOVO) reached a new milestone. Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA for people with type 2 diabetes. It offers people an alternative to daily basal insulin injections, reducing these injections from seven to only one per week. Aside from convenience, this development has large benefits to the unit economics, both for Novo Nordisk and its customers. Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026.